Thermo Fisher Scientific and Cedars-Sinai partner on LC-MS based workflows for clinical labs


Thermo Fisher Scientific and Cedars-Sinai are collaborating on the development of reliable, specific and sensitive liquid chromatography-mass spectrometry based workflows for clinical laboratories that will deliver increased confidence in data while detecting and analyzing novel or known protein-based biomarkers within biological matrices.

Principal investigator for research and director of the Advanced Clinical Biosystems Institute in the Department of Biomedical Sciences at Cedars-Sinai, Jennifer Van Eyk, said, "Thermo Fisher shares our vision for helping clinical research teams set new standards for excellence and innovation in patient care through precision medicine. The goal is to develop advanced LC-MS-based workflows for the untargeted screening and targeted quantitation of protein-based biomarkers for critical disease states, which hold the potential to benefit not only our own patients, but also the wider clinical community."

“Thermo Fisher Scientific and Cedars-Sinai are collaborating on the development on workflows for clinical laboratories.“

Bradley Hart, senior director, clinical marketing, chromatography and mass spectrometry, Thermo Fisher Scientific, said: "As the pathway to precision medicine advances in the lab, reliable and routine analytical workflows will be essential to quantify targeted and untargeted proteins and peptides in clinical samples with greater ease and sensitivity. New LC-MS-based methods will be developed to deliver high quality and confident results regardless of user expertise and experience for laboratories seeking to identify novel biomarkers and monitor biotherapeutics, ultimately helping clinical research teams track and improve outcomes."

See all the latest jobs in Science
Return to news